Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

ns help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the clinical results of the Phase 3 (GOUT 1 and GOUT 2) clinical trials and the interim results from the ongoing Open Label Extension (OLE) (GOUT 3) study for Puricase(R) (pegloticase), the filing, based on those results, of a BLA with the FDA, the filing of a Marketing Authorization Application with the EMEA, the results of the pre-BLA meeting with the FDA and its potential impacts on the BLA submission, the timing of approval of the BLA and launch of pegloticase, the market for pegloticase, and the absence of other therapies for treatment-failure gout patients, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our current assessment of the Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions, varying interpretations of our clinical and CMC data by the FDA, delay achieving or failure to achieve FDA approval of pegloticase, difficulties of expanding our product portfolio through in-licensing or acquisition; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , 27. März 2015 ... Vilcek Prize in Biomedical Science für seine ... wie Proteine zwischen Zellkompartimenten transportiert werden, sowie ... den Zellen zur Reaktion auf Stress nutzen, ... zusammenhängt. Dr. Walter ist Professor für Biochemie ...
(Date:3/27/2015)... 27, 2015   SurePure, Inc . (OTCQB: ... today that the Company has completed the verification ... of SurePure ("SURP") securities on OTCQB, an electronic ... and development stage companies. On March ... eligibility requirements designed to improve marketplace integrity and ...
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Pa., Sept. 23 Environmental,Tectonics Corporation,s (Amex: ... announced the sale and placement of two BARA-MED(R) ... The,Shoreline Facility was established in Corpus Christi, Texas, ... care medical center in the region. The,facility offers ...
... Premacure to Initiate Phase II Trial for IPLEX(TM) ... UPPSALA, Sweden, Sept. 23 ,Insmed Inc. (Nasdaq CM: ... and Premacure AB, a biopharmaceutical company,dedicated to the ... due to premature birth, today noted the presentation ...
... Vein Recognition Device Helps BayCare Accurately,Identify Patients, ... Patient Privacy, SUNNYVALE, Calif., Sept. 23 ... leading supplier of innovative computer products,including hard ... announced that BayCare Health System, the largest ...
Cached Biology Technology:Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 2Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 4Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 5Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 2Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 3Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 4Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 5
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... BERKELEY, CA -- A link between the immune system ... themselves of obsolete or toxic parts may one day ... other deadly infectious diseases. Scientists with the U.S. Department ... have discovered proteins residing in both systems that point ...
... A study in the Sept. 21 on-line edition ... interaction of a critical molecule involved in cell death ... blocking this molecule, called Cyclophilin D (CypD), and development ... for the prevention and treatment of Alzheimer,s disease, according ...
... It seems that our brain can correct speech errors in ... Niels Schiller and Lesya Ganushchak, NWO researchers in Leiden, made ... errors. This research can contribute to improvements in the treatment ... language. Our brain is fairly good at preventing ...
Cached Biology News:Proteomics study yields clues as to how tuberculosis might be thwarting the immune system 2Proteomics study yields clues as to how tuberculosis might be thwarting the immune system 3Mitochondria could be a target for therapeutic strategy for Alzheimer's disease patients 2Brain recognizes verbal 'oh dear' wave 2
... is a new product number, created ... If showing no availability yet, please ... (Z71,487-9) or contact customer service for ... 100 mm, No. of sidearm 4 ...
... pYD1 Yeast Display Vector is specifically designed ... the surface of Saccharomyces cerevisiae. Displayed proteins ... interact with known or putative ligands. pYD1 ... consists of two domains Aga1 and Aga2 ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S ... The gamma secretase is a multiprotein ... and Pen-2; all four proteins are ... gamma secretase complex catalyzes cleavage of ...
Biology Products: